1 |
Baer, G.S, D.H. Ebert, C.J. Chung, A.H. Erickson, and T.S. Dermody. 1999. Mutant cells selected during persistent reovirus infection do not express mature cathepsin L and do not support reovirus disassembly. J. Virol. 73, 9532-9543
PUBMED
|
2 |
Carroll, P.E, M. Okuda, H.F. Horn, P. Biddinger, P.J. Stambrook, L.L. Gleich, Y.Q. Li, P. Tarapore, and K. Fukasawa. 1999. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18, 1935-1944
DOI
|
3 |
Kim, M. 2005. Mechanisms of resistance to reoviral oncolysis. Ph. D. Thesis. University of Calgary, Alberta, Canada
|
4 |
Loken, S.D., K. Norman, K. Hirasawa, M. Nodwell, W.M. Lester, and D.J. Demetrick. 2004. Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anticancer biotherapeutic. Cancer Biol. Ther. 3, 734-73
DOI
PUBMED
ScienceOn
|
5 |
McFadden, G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3, 201-213
DOI
ScienceOn
|
6 |
Russell, S.J. 2002. RNA viruses as virotherapy agents. Cancer Gene Ther. 9, 961-966
DOI
ScienceOn
|
7 |
Sabin, A.B. 1959. Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science 130, 1387-1389
DOI
ScienceOn
|
8 |
Takai, Y., T. Sasaki, and T. Matozaki. 2001. Small GTP-binding proteins. Physiol. Rev. 81, 153-208
DOI
PUBMED
|
9 |
Weiner, H.L., D. Drayna, D.R. Averill, Jr., and B.N. Fields. 1977. Molecular basis of reovirus virulence: role of the S1 gene. Proc. Natl. Acad. Sci. USA 74, 5744-5748
|
10 |
Egan, C., M. Kim, and R.N. Johnston. 2003. Increased expression of human c-Myc renders cells sensitive to reovirus oncolysis. AACR Annual General Meeting, Washington, D.C., USA
|
11 |
Lun, X., W. Yang, T. Alain, Z.Q. Shi, H. Muzik, J.W. Barrett, G. McFadden, J. Bell, M.G. Hamilton, D.L. Senger, and P.A. Forsyth. 2005. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 65, 9982-9990
DOI
ScienceOn
|
12 |
Kim, M., N. Nieden, S.D. Loken, S.J. Urbanski, P.W.K. Lee, D.E. Rancourt, and R.N. Johnston. 2007b. Safety of attenuated reovirus on the developmental potential of embryonic stem cells. The 4th International Conference on Oncolytic Viruses As Cancer Therapeutics. Scottsdale, AZ, USA
|
13 |
Duursma, A.M. and R. Agami. 2003. Ras interference as cancer therapy. Semin. Cancer Biol. 13, 267-273
DOI
ScienceOn
|
14 |
Alain, T., M. Kim, R.N. Johnston, S.J. Urbanski, A.E. Kossakowska, P.A.J. Forsyth, and P.W.K. Lee. 2006. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br. J. Cancer 95, 1020-1027
DOI
ScienceOn
|
15 |
Heinzerling, L., V. Kunzi, P.A. Oberholzer, T. Kundig, H. Naim, and R. Dummer. 2005. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106, 2287-2294
DOI
ScienceOn
|
16 |
Dichter, M.A. and H.L. Weiner. 1984. Infection of neuronal cell cultures with reovirus mimics in vitro patterns of neurotropism. Ann. Neurol. 16, 603-610
DOI
ScienceOn
|
17 |
Coffey, M.C., J.E. Strong, P.A. Forsyth, and P.W. Lee. 1998. Reovirus therapy of tumors with activated Ras pathway Science 282, 1332-1334
DOI
ScienceOn
|
18 |
Ring, C.J. Cytolytic viruses as potential anti-cancer agents. 2002. J. Gen. Virol. 83, 491-502
DOI
PUBMED
|
19 |
Tyler, K.L. 2001. Mammalian reoviruses, p. 1729-1745. In B.N. Fields, D.M. Knipe, and P.M. Howley (eds), Fields Virology, Lippincott-Raven, Philadelphia, USA
|
20 |
Bischoff, J.R., D.H. Kirn, A.Williams, C. Heise, S. Horn, M. Muna, L. Ng, J.A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373- 376
DOI
PUBMED
ScienceOn
|
21 |
Weiner, H.L., M.L. Powers, and B.N. Fields. 1980. Absolute linkage of virulence and central nervous system cell tropism of reoviruses to viral hemagglutinin. J. Infect. Dis. 141, 609-616
DOI
PUBMED
ScienceOn
|
22 |
Wang, G., J.W. Barrett, M. Stanford, S.J. Werden, J.B. Johnston, X. Gao, M. Sun, J.Q. Cheng, and G. McFadden. 2006. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl. Acad. Sci. USA 103, 4640-4645
|
23 |
Baty, C.J. and B. Sherry. 1993. Cytopathogenic effect in cardiac myocytes but not in cardiac fibroblasts is correlated with reovirus- induced acute myocarditis. J. Virol. 67, 6295-6298
PUBMED
|
24 |
Stojdl, D.F., B. Lichty, S. Knowles, R. Marius, H. Atkins, N. Sonenberg, and J.C. Bell. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825
DOI
ScienceOn
|
25 |
Stojdl, D.F., B.D. Lichty, B.R. TenOever, J.M. Paterson, A.T. Power, S. Knowles, R. Marius, J. Reynerd, L. Poliquin, H. Atkins, E.G. Brown, R.K. Durbin, J.E. Durbin, J. Hiscott, and J.C. Bell. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 4, 263-275
DOI
ScienceOn
|
26 |
Hashiro, G., P.C. Loh, and J.T. Yau. 1977. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch. Virol. 54, 307-315
DOI
|
27 |
Richardson, S.C., R.F. Bishop, and A.L. Smith. 1994. Reovirus serotype 3 infection in infants with extrahepatic biliary atresia or neonatal hepatitis. J. Gastroenterol. Hepatol. 9, 264-268
DOI
ScienceOn
|
28 |
Kim, J.H., Y.S. Lee, H. Kim, J.H. Huang, A.R. Yoon, and C.O. Yun. 2006. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction and efficacy. J. Natl. Cancer Inst. 98, 1482-1493
DOI
PUBMED
ScienceOn
|
29 |
Haller, B.L, M.L. Barkon, G.P. Vogler, and H.W. Virgin 4th. 1995. Genetic mapping of reovirus virulence and organ tropism in severe combined immunodeficient mice: organ-specific virulence genes. J. Virol. 69, 357-364
PUBMED
|
30 |
Kim, M., C. Egan, T. Alain, S.J. Urbanski, P.W.K. Lee, P.A.J. Forsyth, and R.N. Johnston. 2007a. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene 26, 4124-4134
DOI
ScienceOn
|
31 |
Minuk, G.Y., R.W. Paul, and P.W. Lee. 1985. The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J. Med. Virol. 16, 55-60
DOI
ScienceOn
|
32 |
Roberts, M.S., R.M. Lorence, W.S. Groene, and M.K. Bamat. 2006. Naturally oncolytic viruses. Curr. Opin. Mol. Ther. 8, 314-321
PUBMED
|
33 |
Steele, T.A. and C.C Hauser. 2005. The role of interferon-alpha in a successful murine tumor therapy. Exp. Biol. Med. 230, 487-493
DOI
|
34 |
Kim, M., T. Alain, S.J. Urbanski, A.E. Kossakowska, P.W.K. Lee, P.A.J. Forsyth, and R.N. Johnston. 2007c. An attenuated reovirus isolated from persistent reovirus infection exerts viral oncolysis with reduced pathogenicity. The 4th International Conference on Oncolytic Viruses As Cancer Therapeutics. Scottsdale, AZ, USA
|
35 |
Nibert, M.L. and L.A. Schiff. 2001. Reoviruses and their replication. p. 1679-1728, In B.N. Fields, D.M Knipe, and P.M. Howley, (eds.). Fields Virology, Lippincott-Raven Publisher, Philadelphia, USA
|
36 |
Norman, K.L. and P.W. Lee. 2005. Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov. Today 10, 847-855
DOI
ScienceOn
|
37 |
Ahmed, M., S.D. Cramer, and D.S. Lyles. 2004. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 330, 34-49
DOI
ScienceOn
|
38 |
Jun, H.S. and J.W. Yoon. 2003. A new look at viruses in type 1 diabetes. Diabetes Metab. Res. Rev. 19, 8-31
DOI
ScienceOn
|
39 |
Steele, T.A. and D.C. Cox. 1995. Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine. Cancer Biother. 10, 307-315
DOI
PUBMED
ScienceOn
|
40 |
Terheggen, F., E. Benedikz, P.H. Frissen, and K. Brinkman. 2003. Myocarditis associated with reovirus infection. Eur. J. Clin. Microbiol. Infect. Dis. 22, 197-198
|
41 |
Morris, S.M. 2002. A role for p53 in the frequency and mechanism of mutation. Mutat. Res. 511, 45-62
DOI
ScienceOn
|
42 |
Alain, T., J.F. Wong, S. Urbanski, P. Lee, A.E. Kossakowska, R.N. Johnston, and P.L. Beck. 2007. Reovirus decreases azoxymethane- induced aberrant crypt foci and colon cancer in a rodent model. Cancer Gene Ther. (in press)
|
43 |
Strong, J.E., M.C. Coffey, D. Tang, P. Sabinin, and P.W. Lee. 1998. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 17, 3351-3362
DOI
ScienceOn
|
44 |
Nakamura, T. and S.J. Russell. 2004. Oncolytic measles viruses for cancer therapy. Expert Opin. Biol. Ther. 4, 1685-1692
DOI
ScienceOn
|
45 |
Bos, J.L. 1989. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689
PUBMED
|
46 |
Ebert, D.H, S.A. Kopecky-Bromberg, and T.S. Dermody. 2004. Cathepsin B is inhibited in mutant cells selected during persistent reovirus infection. J. Biol. Chem. 279, 3837-3851
DOI
ScienceOn
|
47 |
Heise, C., T. Hermiston, L. Johnson, G. Brooks, A. Sampson- Johannes, A. Williams, L. Hawkins, and D. Kirn. 2000. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134-1139
DOI
ScienceOn
|
48 |
Mann, M.A, K.L. Tyler, D.M Knipe, and B.N. Fields. 2002. Type 3 reovirus neuroinvasion after intramuscular inoculation: viral genetic determinants of lethality and spinal cord infection. Virology 303, 213-221
DOI
ScienceOn
|
49 |
Ebert, O., S. Harbaran, K. Shinozaki, and S.L. Woo. 2005. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther. 12, 350-358
DOI
ScienceOn
|
50 |
Dermody, T.S. 1998. Molecular mechanisms of persistent infection by reovirus. Curr. Top Microbiol. Immunol. 233(Pt 2), 1-22
PUBMED
|
51 |
Thorne, S.H., D.L. Bartlett, and D.H. Kirn. 2005. The use of oncolytic Vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr. Gene Ther. 5, 429-443
DOI
|
52 |
Duncan, M.R., S.M. Stanish, and D.C. Cox. 1978. Differential sensitivity of normal and transformed human cells to reovirus infection. J. Virol. 28, 444-449
PUBMED
|
53 |
Ahmed, R., W.M. Canning, R.S. Kauffman, A.H. Sharpe, J.V. Hallum, and B.N. Fields. 1981. Role of the host cell in persistent viral infection: coevolution of L cells and reovoirus during persistent infection. Cell 25, 325-332
DOI
ScienceOn
|
54 |
Heggie, A.D. and L. Gaddis. 1979. Effects of viral exposure of the two-cell mouse embryo on cleavage and blastocyst formation in vitro. Pediatr. Res. 13, 937-941
DOI
PUBMED
|
55 |
Jackson, G.G. and R.L. Muldoon. 1973. Viruses causing common respiratory infection in man. IV. Reoviruses and adenoviruses. J. Infect. Dis. 128, 811-833
DOI
PUBMED
ScienceOn
|
56 |
Priscott, P.K. 1983. The growth of reovirus 3 in cultured rat embryos and implications for human reproductive failure. Br. J. Exp. Pathol. 64, 467-473
PUBMED
|
57 |
Rosen, L., H.E. Evans, and A. Spickard. 1963. Reovirus infections in human volunteers. Am. J. Epidemiol. 77, 29-37
DOI
|
58 |
Kirn, D. 2001. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin. Biol. Ther. 1, 525-538
DOI
ScienceOn
|
59 |
Stoeckel, J. and J.G. Hay. 2006. Drug evaluation: Reolysin-wild-type reovirus as a cancer therapeutic. Curr. Opin. Mol. Ther. 8, 249-260
PUBMED
|
60 |
DeBiasi, R.L., B.A. Robinson, B. Sherry, R. Bouchard, R.D. Brown, M. Rizeq, C. Long, and K.L. Tyler. 2004. Caspase inhibition protects against reovirus-induced myocardial injury in vitro and in vivo. J. Virol. 78, 11040-11050
DOI
ScienceOn
|
61 |
Minuk, G.Y., N. Rascanin, R.W. Paul, P.W. Lee, K. Buchan, and J.K. Kelly. 1987. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 5, 8-13
DOI
|
62 |
Strong, J.E. and P.W. Lee. 1996. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J. Virol. 70, 612-616
PUBMED
|